Revelation Biosciences
REVB
12 hedge funds and large institutions have $50M invested in Revelation Biosciences in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 9 → 12 (+3)
27% more capital invested
Capital invested by funds: $39.3M → $50M (+$10.8M)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$2.05M |
| 2 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$2.05M |
| 3 |
Millennium Management
New York
|
+$2.05M |
| 4 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSU
Mizuho Securities USA
New York
|
-$621K |
REVB Hedge Fund Activity: Q1 2021 in Review
12 of the 5,710 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences (REVB) for Q1 2021, worth a combined $50M — up 27% from $39.3M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new REVB positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was CVI Holdings, opening a new position worth an estimated $2.05M. The largest seller was Mizuho Securities USA, cutting an estimated $621K.
- 12 institutional investors held Revelation Biosciences (REVB) as of Q1 2021, up from 9 in Q4 2020.
- Funds reported $50M of Revelation Biosciences stock for Q1 2021, up 27% quarter-over-quarter.
- 3 funds opened new Revelation Biosciences positions in Q1 2021 and 0 closed out, a net change of +3 holders.
- The largest Revelation Biosciences buyer in Q1 2021 was CVI Holdings, an estimated $2.05M added.
- The largest Revelation Biosciences seller in Q1 2021 was Mizuho Securities USA, an estimated $621K sold.
Based on aggregated 13F filings for Q1 2021.